Marcella Ruddy

AVROBIO, Inc. engages in the development of lentiviral-based gene therapies. It focuses on developing potentially curative ex vivo lentiviral-based gene therapies to treat patients with rare diseases following a single dose treatment regimen. The firm's clinical-stage programs include Fabry, Gaucher Type 1, Hunter syndrome Gaucher Type 3, Pompe, and Cystinosis. The company was founded by Geoff Mackay, Kim Warren, Christopher Mason, and Jeffrey Medin in 2015 and is headquartered in Watertown, MA.

Tectonic Therapeutic, Inc. is a biotech company based in Watertown, MA. Tectonic is focused on transforming the discovery of antibodies and other biologic drugs targeting G-protein coupled receptors (GPCRs) to develop novel therapies for patients inadequately served by current treatments. The company's proprietary Geode platform aims to unlock the therapeutic utility of the most difficult receptors in the class, which have been considered undruggable with small molecules. The company was founded by Timothy A. Springer and Andrew Kruse of Harvard Medical School. Alise S. Reicin has been the CEO of the company since 2020.

Upstream Bio, Inc. is a clinical-stage biopharmaceutical company based in Waltham, MA, USA. The American company's lead program, upb-101, is a monoclonal antibody that inhibits the TSLP receptor, a validated target that affects various immune cells involved in common and rare diseases. Upstream Bio is leveraging its diverse roots and substantial industry experience to develop therapies that ease the burden of inflammatory and allergic diseases on patients and their loved ones. The company was founded by Eran Perry and Earn Perry, and Samantha Truex has been the CEO since 2021.